Swiss National Bank Has $609,000 Stock Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Swiss National Bank grew its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 12.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 112,400 shares of the company’s stock after buying an additional 12,400 shares during the quarter. Swiss National Bank owned approximately 0.16% of Eyepoint Pharmaceuticals worth $609,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Virtus ETF Advisers LLC acquired a new position in shares of Eyepoint Pharmaceuticals in the fourth quarter worth about $67,000. Raymond James Financial Inc. purchased a new stake in shares of Eyepoint Pharmaceuticals in the fourth quarter worth approximately $76,000. GAMMA Investing LLC lifted its position in shares of Eyepoint Pharmaceuticals by 3,174.4% in the first quarter. GAMMA Investing LLC now owns 10,249 shares of the company’s stock worth $56,000 after purchasing an additional 9,936 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Eyepoint Pharmaceuticals in the fourth quarter worth approximately $91,000. Finally, Invesco Ltd. lifted its position in shares of Eyepoint Pharmaceuticals by 16.1% in the fourth quarter. Invesco Ltd. now owns 15,657 shares of the company’s stock worth $117,000 after purchasing an additional 2,177 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, June 17th. They issued an “outperform” rating and a $28.00 price target for the company. Mizuho reduced their price target on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Friday, May 16th. HC Wainwright increased their price target on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, August 6th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $27.00 price objective on shares of Eyepoint Pharmaceuticals in a research report on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $25.38.

Eyepoint Pharmaceuticals Stock Performance

Shares of EYPT opened at $12.04 on Wednesday. The firm has a market cap of $829.92 million, a PE ratio of -4.49 and a beta of 1.73. The firm’s 50 day moving average price is $10.28 and its 200 day moving average price is $7.75. Eyepoint Pharmaceuticals, Inc. has a twelve month low of $3.91 and a twelve month high of $13.98.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. The firm had revenue of $5.33 million during the quarter, compared to the consensus estimate of $6.82 million. On average, sell-side analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.